Back to results
US 2014/0155436 A1Published application
Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies
AssigneesCentre National De Recherche Scientifique, Universite Montpellier 2 Sciences Et Techniques, Institut Curie
InventorsJamal TAZI, David GRIERSON, Florence MAHUTEAU-BETZER, Pierre ROUX
Life of this patent
Estimating the term…
Abstract
The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.
Claims9
A compound having the following formula:
- wherein,
- X2 represents a nitrogen atom or a CR16 group with R16 being a hydrogen atom or a
- group;
- R4 represents a hydrogen atom or a C1 to C3 alkyl group or a C(═O)NR14R15 group with R4 representing a hydrogen atom or a C1 to C3 alkyl group when R5 or R6 is different than a hydrogen atom;
- R5 represents a hydrogen atom, a C(═O)NR14R15 group or a
- group with R5 representing a hydrogen atom when R4 or R6 is different than a hydrogen atom;
- R6 represents a hydrogen atom, or a C(═O)NR14R15 group or a
- group with R6 representing a hydrogen atom when R5 is different than a hydrogen atom or when R4 is different than a hydrogen atom or a C1 to C3 alkyl group;
- R7 represents a hydrogen atom, an NR11R12 or OR12 group with R11 and R12 representing independently of the other a hydrogen atom or a C1 to C3 alkyl group, with X2 representing a CH group when R7 represents an NR11R12 or OR12 group;
- X1 represents a nitrogen atom, a NR11 group or a CR10 group with R10 being a hydrogen atom or an NR11R12 or OR11 group with R11 and R12 being as defined above;
- R1 represents a hydrogen atom, an NR11R12 group, or OR12 group with R11 and R12 being as defined above, with X1 representing a CH group when R1 represents an NR11R12 or OR12 group;
- A represents a
- amide group or a
- alcene group;
- R14 and R15 represent independently of the other:
- a hydrogen atom, or
- a linear or branched C1 to C10 alkyl group, wherein one or more carbon atoms can be substituted by a nitrogen atom, said alkyl group optionally being substituted by one or more —OH and/or ═O groups and/or by:
- which may be substituted or unsubstituted;
- R21 and R22 represent independently of the other a hydrogen atom or a methyl group;
- or
- being a pharmaceutically acceptable salt or isomer thereof.
18 more elements
A compound selected from the group consisting of:
- N-(3-Dimethylamino-propyl)-3-(4-trifluoromethoxy-phenylamino)-benzamide;
- 4-(4-Methoxy-phenylamino)-3-methyl-N-(3-methyl-butyl)-benzamide;
- 3-Methyl-N-(3-methyl-butyl)-4-(4-trifluoromethoxy-phenylamino)-benzamide;
- N-(2-Dimethylamino-ethyl)-2-(4-trifluoromethoxy-phenylamino)-benzamide;
- N-(2-Diethylamino-ethyl)-2-(4-trifluoromethoxyphenylamino)-benzamide;
- N-(2-Diethylamino-propyl)-2-(4-trifluoromethoxy-phenylamino)-benzamide;
- (N-Diethylamino)-{1-[4-(4-Methoxy-phenylamino)-phenyl]-1H-1,2,3-triazol-4-yl}-methylamine;
- (N-Diethylamino)-{1-[4-(4-trifluoromethoxyphenylamino)-phenyl]-1H-1,2,3-triazol-4-yl}-methylamine;
- (N-Diethylamino)-{1-[4-(4-N-dimethylamino-phenylamino)-phenyl]-1H-1,2,3-triazol-4-yl}-methylamine;
- N-(3-Imidazol-1-yl-propyl)-2-(4-methoxy-phenylamino)-benzamide;
- N-(3-Imidazol-1-yl-propyl)-2-(4-trifluoromethoxy-phenylamino)-benzamide;
- 2-(4-Dimethylamino-phenylamino)-N-(3-imidazol-1-yl-propyl)-benzamide;
- N-(4-Diethylamino-1-methyl-butyl)-2-(4-dimethylaminophenylamino)-benzamide;
- N-(2-Dimethylamino-ethyl)-4-(4-trifluoromethoxy-phenylamino)-benzamide;
- N-(2-Dimethylamino-ethyl)-4-(4-dimethylamino-phenylamino)-benzamide;
- N-(2-Dimethylamino-ethyl)-4-(4-methoxy-phenylamino)-3-methyl-benzamide;
- N-(3-Diethylamino-propyl)-4-(4-methoxy-phenylamino)-benzamide;
- N-(3-Diethylamino-propyl)-4-(4-methoxy-phenylamino)-3-methyl-benzamide;
- N-(3-Diethylamino-propyl)-3-methyl-4-(4-trifluoromethoxy-phenylamino)-benzamide;
- N-(3-Diethylamino-propyl)-4-(4-dimethylamino-phenylamino)-3-methyl-benzamide;
- N-(2-Dimethylamino-ethyl)-3-methyl-4-(4-trifluoromethoxy-phenylamino)-benzamide;
- 3-{1-[4-(4-Methoxy-phenylamino)-phenyl]-1H-1,2,3-triazol-4-yl}-propan-1-ol;
- (N-diethylamino)-{1-[3-(4-Methoxy-phenylamino)-phenyl]-1H-1,2,3-triazol-4-yl}-methylamine;
- [4-(5-Chloro-1H-imidazol-2-yl)-2-methyl-phenyl]-(4-methoxy-phenyl)-amine;
- N-(2-Diethylamino-ethyl)-4-(4-methoxy-phenylamino)-benzamide;
- N-(2-Dimethylamino-ethyl)-2-(4-methoxy-phenylamino)-benzamide;
- 4-(4-Methoxy-phenylamino)-N-(3-methyl-butyl)-benzamide;
- N-(3-Imidazol-1-yl-propyl)-4-(4-trifluoromethoxy-phenylamino)-benzamide;
- [3-(4-Diethylaminomethyl-[1,2,3]triazol-1-yl)-phenyl]-(4-dimethylamino)-phenylamine;
- N-(2-Diethylamino-ethyl)-2-(4-methoxy-phenylamino)-benzamide;
- 3-{1-[3-(4-Trifluoromethoxy-phenylamino)-phenyl]-1H-[1,2,3]triazol-4-yl}-propan-1-ol;
- 3-{1-[3-(4-Dimethylamino-phenylamino)-phenyl]-1H-[1,2,3]triazol-4-yl}-propan-1-ol;
- and
- pharmaceutically acceptable salts thereof.
31 more elements
Dependencies are inferred from the claim text.